While the complete roles of Nav1.1 and Nav1.6 throughout AD progression remain to be elucidated, their contributions to early-stage hyperactivity are under investigation and may prove critical to the development of disease-modifying AD therapeutics. This evidence concerns the gene SCN1A and Alzheimer disease.